A recent patient-led case series highlights the potential benefits of extended courses of

最近的一个以患者为主导的病例系列强调了延长疗程的潜在益处

Pfizer Inc's

辉瑞公司

PFE

PFE

Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID.

奈玛特韦片/利托那韦片组合包装（尼马特雷韦/利托那韦）用于长期COVID患者。

The study documents mixed outcomes among 13 participants, with some reporting meaningful symptom relief and others seeing little to no benefit. The findings underscore the need for more robust clinical research to evaluate the drug's efficacy in managing persistent symptoms of the condition.

该研究记录了13名参与者的混合结果，其中一些人报告有意义的症状缓解，另一些人几乎没有任何益处。这些发现强调了需要更强有力的临床研究来评估该药物在治疗持续症状方面的疗效。

Also Read:

另请阅读：

Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study

辉瑞公司的Paxlovid证明了安全性，但对低风险Covid-19患者NEJM研究的疗效提出了质疑

The

The

study

学习

involved patients aged 25 to 55 who were infected with SARS-CoV-2 between March 2020 and December 2022 and experienced symptoms such as fatigue, brain fog, muscle pain, irregular heart rate, and post-exertional malaise.

涉及2020年3月至2022年12月期间感染SARS-CoV-2的25至55岁患者，并出现疲劳，脑雾，肌肉疼痛，心率不规则和劳累后不适等症状。

Participants took Paxlovid courses ranging from 7.5 to 30 days, often in combination with other medications or supplements, complicating the assessment of the drug's isolated effects.

参与者参加了7.5至30天的Paxlovid课程，通常与其他药物或补充剂联合使用，使药物单独作用的评估变得复杂。

While some participants experienced sustained improvement, others noted temporary relief or no change.

虽然一些参与者经历了持续的改善，但其他人注意到暂时缓解或没有变化。

Two patients who took extended Paxlovid courses during acute reinfections reported eventual recovery to their pre-reinfection baseline. Another participant discontinued the treatment early due to severe stomach pain, highlighting the need to consider potential side effects.

两名在急性再感染期间延长Paxlovid疗程的患者报告最终恢复到再感染前的基线。另一名参与者由于严重的胃痛而提前停止治疗，强调需要考虑潜在的副作用。

The study acknowledges its limitations, including small, non-representative sample size and reliance on self-reported data, which may introduce recall or fatigue bias.

该研究承认其局限性，包括样本量小，不具代表性，以及依赖自我报告的数据，这可能会导致回忆或疲劳偏见。

However, its participatory approach sheds light on lived experiences that traditional medical records may overlook.

然而，它的参与式方法揭示了传统医疗记录可能忽视的生活经历。

Extended antiviral courses have precedent in other conditions like HIV and hepatitis C, suggesting a basis for further exploration in Long COVID.

延长抗病毒疗程在艾滋病毒和丙型肝炎等其他疾病中也有先例，这为进一步探索长冠状病毒奠定了基础。

Researchers are encouraged to investigate potential treatment pathways, including optimal course lengths and symptom recurrence post-treatment. Larger clinical

。较大的临床

trials

试验

are underway to systematically evaluate these factors.

正在进行系统评估这些因素。

Currently, no FDA-approved treatments specifically target Long COVID. If clinical trials validate Paxlovid's benefits, regulatory pathways like expanded access or fast-track designation could help make the drug available to patients.

目前，没有FDA批准的治疗方法专门针对长COVID。如果临床试验验证了Paxlovid的益处，那么扩大获取或快速通道指定等监管途径可能有助于患者获得该药物。

Last year, the FDA updated the emergency use

去年，FDA更新了紧急使用

authorization for Paxlovid

Paxlovid授权

.

.

Price Action:

价格行动：

PFE stock is up 0.49% at $26.72 during the premarket session at last check Monday.

在周一最后一次检查的上市前交易中，PFE股价上涨0.49%，至26.72美元。

Read Next:

Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug

诺和诺德（Novo Nordisk）敦促美国食品和药物管理局（FDA）排除其早期糖尿病药物的复配

Photo via Company

通过公司拍照

Market News and Data brought to you by Benzinga APIs

Benzinga API为您带来的市场新闻和数据

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

。保留所有权利。